Status:
ACTIVE_NOT_RECRUITING
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Colorectal Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of c...
Eligibility Criteria
Inclusion
- Unresectable colorectal cancer
- Life expectancy of at least 3 months
- Patients with ECOG performance status 0 or 1
Exclusion
- Patients with severe complication
- Patients are unable to swallow oral medications
Key Trial Info
Start Date :
January 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06547385
Start Date
January 13 2021
End Date
October 31 2027
Last Update
August 9 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
2
Kobe City Hospital Organization Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
3
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
4
Saitama Cancer Center
Ina, Kitaadati-gun, Saitama, Japan